zileuton has been researched along with ubenimex in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Ahmadieh, H; Hafezi-Moghadam, A; Ishibashi, T; Ishikawa, K; Kanavi, MR; Koga, T; Nakama, T; Nakao, S; Ohba, M; Okuno, T; Penninger, JM; Saeki, K; Sasaki, F; Sonoda, KH; Yokomizo, T; Yoshida, S | 1 |
2 other study(ies) available for zileuton and ubenimex
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models.
Topics: Animals; Benzopyrans; Carboxylic Acids; Choroidal Neovascularization; Disease Models, Animal; Eye; Eye Injuries; Hydroxyurea; Indoles; Lasers; Leucine; Leukotriene B4; Macrophages; Macular Degeneration; Male; Mice; Mice, Knockout; Neovascularization, Pathologic; Receptors, Leukotriene B4; Signal Transduction | 2018 |